Michael Chi Sells 17,303 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Michael Chi sold 17,303 shares of the stock in a transaction on Monday, February 24th. The shares were sold at an average price of $48.14, for a total transaction of $832,966.42. Following the completion of the sale, the insider now owns 193,601 shares of the company’s stock, valued at approximately $9,319,952.14. This represents a 8.20 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Michael Chi also recently made the following trade(s):

• On Monday, February 10th, Michael Chi sold 7,259 shares of Hims & Hers Health stock. The shares were sold at an average price of $43.28, for a total transaction of $314,169.52.
• On Friday, January 24th, Michael Chi sold 17,304 shares of Hims & Hers Health stock. The shares were sold at an average price of $31.00, for a total transaction of $536,424.00.
• On Friday, January 10th, Michael Chi sold 7,259 shares of Hims & Hers Health stock. The stock was sold at an average price of $24.07, for a total transaction of $174,724.13.
• On Tuesday, December 24th, Michael Chi sold 17,303 shares of Hims & Hers Health stock. The shares were sold at an average price of $27.97, for a total value of $483,964.91.
• On Thursday, December 19th, Michael Chi sold 7,500 shares of Hims & Hers Health stock. The stock was sold at an average price of $26.00, for a total value of $195,000.00.
• On Tuesday, December 10th, Michael Chi sold 7,259 shares of Hims & Hers Health stock. The shares were sold at an average price of $32.25, for a total value of $234,102.75.
• On Monday, December 2nd, Michael Chi sold 2,054 shares of Hims & Hers Health stock. The stock was sold at an average price of $33.56, for a total value of $68,932.24.

Hims & Hers Health Price Performance

NYSE:HIMS traded down $11.37 during trading hours on Tuesday, hitting $39.95. The company’s stock had a trading volume of 82,446,262 shares, compared to its average volume of 21,013,705. The company has a market capitalization of $8.73 billion, a P/E ratio of 90.79 and a beta of 1.35. Hims & Hers Health, Inc. has a twelve month low of $9.67 and a twelve month high of $72.98. The stock has a fifty day simple moving average of $35.45 and a 200-day simple moving average of $26.08.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, beating analysts’ consensus estimates of $0.09 by $0.02. The company had revenue of $481.14 million for the quarter, compared to the consensus estimate of $494.56 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. On average, equities analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Wall Street Analyst Weigh In

HIMS has been the topic of a number of recent research reports. BTIG Research initiated coverage on shares of Hims & Hers Health in a research report on Tuesday, January 7th. They set a “buy” rating and a $35.00 price target on the stock. Piper Sandler increased their target price on shares of Hims & Hers Health from $24.00 to $35.00 and gave the stock a “neutral” rating in a research report on Tuesday. Needham & Company LLC lifted their price target on shares of Hims & Hers Health from $31.00 to $61.00 and gave the company a “buy” rating in a research report on Tuesday. Deutsche Bank Aktiengesellschaft increased their price target on Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research report on Wednesday, November 6th. Finally, Canaccord Genuity Group raised their price objective on Hims & Hers Health from $38.00 to $68.00 and gave the stock a “buy” rating in a research note on Wednesday, February 19th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $33.40.

Institutional Trading of Hims & Hers Health

A number of hedge funds and other institutional investors have recently modified their holdings of HIMS. Farallon Capital Management LLC boosted its holdings in shares of Hims & Hers Health by 64,338.5% during the 4th quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company’s stock valued at $202,556,000 after acquiring an additional 8,364,000 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its stake in shares of Hims & Hers Health by 192.0% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company’s stock valued at $152,436,000 after purchasing an additional 4,145,305 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Hims & Hers Health by 11.1% during the fourth quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company’s stock valued at $489,817,000 after purchasing an additional 2,020,722 shares in the last quarter. Yong Rong HK Asset Management Ltd bought a new stake in shares of Hims & Hers Health during the fourth quarter worth about $41,104,000. Finally, Renaissance Technologies LLC increased its stake in shares of Hims & Hers Health by 29.0% in the fourth quarter. Renaissance Technologies LLC now owns 6,951,152 shares of the company’s stock valued at $168,079,000 after buying an additional 1,562,302 shares during the period. Institutional investors own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.